Woods K - Search Results

1

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Vella LJ, Andrews MC, Behren A, Cebon J, Woods K. Vella LJ, et al. Among authors: woods k. Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Expert Rev Clin Immunol. 2014. PMID: 24939732 Review.

2

Tumor-specific T-cell help is associated with improved survival in melanoma.

Woods K, Cebon J. Woods K, et al. Clin Cancer Res. 2013 Aug 1;19(15):4021-3. doi: 10.1158/1078-0432.CCR-13-1349. Epub 2013 Jul 17. Clin Cancer Res. 2013. PMID: 23864163

3

Evolving role of tumor antigens for future melanoma therapies.

Andrews MC, Woods K, Cebon J, Behren A. Andrews MC, et al. Among authors: woods k. Future Oncol. 2014 Jun;10(8):1457-68. doi: 10.2217/fon.14.84. Future Oncol. 2014. PMID: 25052755 Review.

4

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS. Vella LJ, et al. Among authors: woods k. Oncoimmunology. 2014 Jul 3;3(7):e946367. doi: 10.4161/21624011.2014.946367. eCollection 2014. Oncoimmunology. 2014. PMID: 25610732 Free PMC article.

5

The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

da Gama Duarte J, Woods K, Andrews MC, Behren A. da Gama Duarte J, et al. Among authors: woods k. Immunol Cell Biol. 2018 May;96(5):497-506. doi: 10.1111/imcb.12001. Epub 2018 Feb 2. Immunol Cell Biol. 2018. PMID: 29392770 Review.

6

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J. Da Gama Duarte J, et al. Among authors: woods k. Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018. Front Immunol. 2018. PMID: 29552014 Free PMC article. Clinical Trial.

7

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J. Klein O, et al. Among authors: woods k. Eur J Immunol. 2013 Feb;43(2):533-9. doi: 10.1002/eji.201242603. Epub 2012 Dec 5. Eur J Immunol. 2013. PMID: 23124877 Free article.

8

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Wong SQ, Behren A, Mar VJ, Woods K, Li J, Martin C, Sheppard KE, Wolfe R, Kelly J, Cebon J, Dobrovic A, McArthur GA. Wong SQ, et al. Among authors: woods k. Oncotarget. 2015 Jan 20;6(2):1115-27. doi: 10.18632/oncotarget.2747. Oncotarget. 2015. PMID: 25544760 Free PMC article.

9

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Woods K, Pasam A, Jayachandran A, Andrews MC, Cebon J. Woods K, et al. Front Oncol. 2014 Dec 17;4:367. doi: 10.3389/fonc.2014.00367. eCollection 2014. Front Oncol. 2014. PMID: 25566505 Free PMC article. Review.

10

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J. Woods K, et al. J Immunother Cancer. 2016 Feb 16;4:10. doi: 10.1186/s40425-016-0111-7. eCollection 2016. J Immunother Cancer. 2016. PMID: 26885372 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

858 results

Search Page

Filters